These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 20507943)

  • 21. Fibroblast growth factor 23/klotho axis in chronic kidney disease.
    Nitta K; Nagano N; Tsuchiya K
    Nephron Clin Pract; 2014; 128(1-2):1-10. PubMed ID: 25402964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of fibroblast growth factor-23 in chronic kidney disease.
    Westerberg PA; Linde T; Wikström B; Ljunggren O; Stridsberg M; Larsson TE
    Nephrol Dial Transplant; 2007 Nov; 22(11):3202-7. PubMed ID: 17567652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M; Koch TA; Bregman DB
    J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical aspect of recent progress in phosphate metabolism. Pathophysiology of secondary hyperparathyroidism in chronic kidney disease].
    Goto S; Fukagawa M
    Clin Calcium; 2009 Jun; 19(6):809-14. PubMed ID: 19483275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum fibroblast growth factor 23 concentrations in dogs with chronic kidney disease.
    Dittmer KE; Perera KC; Elder PA
    Res Vet Sci; 2017 Oct; 114():348-350. PubMed ID: 28667925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease?
    Stubbs JR; Quarles LD
    Nephrol News Issues; 2009 May; 23(6):33-4, 36-7. PubMed ID: 19534362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease.
    Spichtig D; Zhang H; Mohebbi N; Pavik I; Petzold K; Stange G; Saleh L; Edenhofer I; Segerer S; Biber J; Jaeger P; Serra AL; Wagner CA
    Kidney Int; 2014 Jun; 85(6):1340-50. PubMed ID: 24402093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FGF23 and mineral metabolism, implications in CKD-MBD.
    Rodríguez M; López I; Muñoz J; Aguilera-Tejero E; Almaden Y
    Nefrologia; 2012 May; 32(3):275-8. PubMed ID: 22592418
    [No Abstract]   [Full Text] [Related]  

  • 30. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.
    Taal MW; Thurston V; McIntyre NJ; Fluck RJ; McIntyre CW
    Kidney Int; 2014 Aug; 86(2):407-13. PubMed ID: 24429404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation.
    Tomida K; Hamano T; Ichimaru N; Fujii N; Matsui I; Nonomura N; Tsubakihara Y; Rakugi H; Takahara S; Isaka Y
    Bone; 2012 Oct; 51(4):729-36. PubMed ID: 22796419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FGF23: a key player in mineral and bone disorder in CKD.
    Komaba H; Fukagawa M
    Nefrologia; 2009; 29(5):392-6. PubMed ID: 19820750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system.
    Prié D; Friedlander G
    Clin J Am Soc Nephrol; 2010 Sep; 5(9):1717-22. PubMed ID: 20798257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo.
    López I; Rodríguez-Ortiz ME; Almadén Y; Guerrero F; de Oca AM; Pineda C; Shalhoub V; Rodríguez M; Aguilera-Tejero E
    Kidney Int; 2011 Sep; 80(5):475-82. PubMed ID: 21525854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate.
    Cancela AL; Oliveira RB; Graciolli FG; dos Reis LM; Barreto F; Barreto DV; Cuppari L; Jorgetti V; Carvalho AB; Canziani ME; Moysés RM
    Nephron Clin Pract; 2011; 117(1):c74-82. PubMed ID: 20689328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
    Weber TJ; Liu S; Indridason OS; Quarles LD
    J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGF23: a mature renal and cardiovascular risk factor?
    Zoccali C; Yilmaz MI; Mallamaci F
    Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PHEX, FGF23, DMP1 and beyond.
    Strom TM; Jüppner H
    Curr Opin Nephrol Hypertens; 2008 Jul; 17(4):357-62. PubMed ID: 18660670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGF23: its role in renal bone disease.
    Fukagawa M; Kazama JJ
    Pediatr Nephrol; 2006 Dec; 21(12):1802-6. PubMed ID: 16932898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
    Nagano N; Miyata S; Abe M; Wakita S; Kobayashi N; Wada M
    Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.